Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasisTop-line data from the 12-week double-blind ...

A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival ...

More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

Super Bowl LIX champion Dallas Goedert of the Philadelphia Eagles shares his journey with plaque psoriasis. After 20 years of ...

We describe 5 patients with moderate to severe chronic plaque psoriasis and 6 patients with psoriatic arthritis that was refractory to conventional systemic and/or topical antipsoriatic treatment ...

Psoriatic arthritis (PsA) is a form of arthritis that affects about one-third of people with psoriasis ... covered with silvery-white scales, called plaques. Plaques may itch, burn, or hurt.

Etanercept is one of the most frequently used TNF blockers, and has been approved for use in not only moderate-to-severe plaque psoriasis but also rheumatoid arthritis, polyarticular juvenile ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced ...

Plaque psoriasis is the most common ... Psoriasis and psoriatic arthritis are different diseases, but they are related. Some people may have both at the same time. Whether you're newly diagnosed ...

psoriatic arthritis, and adults with chronic moderate-to-severe plaque psoriasis. In clinical trials, the most common adverse effect of this treatment was injection site reaction (ISR).

Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis: Princeton, New Jersey Tuesday, February 18, 2025, 1 ...

No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile ...